Jane Osbourn joined SV as a Venture Partner in 2020. She is Chief Scientific Officer for Alchemab Therapeutics, an SV portfolio company focused on identifying self-protective antibodies as therapies for neurodegeneration and oncology.
Prior to joining Alchemab, Jane served as VP of R&D at MedImmune, the biologics arm of AstraZeneca, where she contributed to the development of phage display technology, authored many key publications and patents and contributed to the discovery and development of a number of antibody therapies including Humira and Durvalumab.
Jane is passionate about the development of the biotechnology sector and served as Chair of the Board of Directors of the UK BioIndustry Association from 2015-2019. She is a Director of Babraham Bioscience Technologies, a Director of Cambridge Enterprise, previously served as a Member of the UK Medical Research Council Industry Grant Award Assessment Panel and is a member of the Crick Translational Advisory Group.
In 2019 Jane was awarded an OBE in the Queen’s birthday honors for services to drug discovery, development and biotechnology, and was also awarded the 2019 Scrip Lifetime Achievement Award for contribution to the pharma industry.
Jane also currently chairs the Cambridge-based cell therapy company Mogrify.
BA in Natural Sciences (Biochemistry) from the University of Cambridge and a PhD, John Innes Centre for Plant Science Research, Norwich